News extra [these stories appear only on the web]

Indian regulators are accused of laxity in not banning drugs

BMJ 2004; 329 doi: 10.1136/bmj.329.7471.878-f (Published 14 October 2004)
Cite this as: BMJ 2004;329:878.7

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Ganapati Mudur
  1. New Delhi

    Doctors and health activists in India have said that they would welcome a government ban on the arthritis drug rofecoxib but warned that there are other drugs withdrawn elsewhere in the world but still sold and prescribed in India.

    They pointed out last week that Indian drug regulatory authorities have refused to ban the sale of 11 other drugs and over 80 combinations of drugs that have been discarded or have never been approved in many countries.

    After the drug company Merck's recent announcement of the worldwide withdrawal of rofecoxib (Vioxx) (BMJ 2004;329:816, 9 October) Indian drug officials said that they would examine Indian data on adverse reactions to decide …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular